Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

Abstract TP53-mutant acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) are characterized by chemotherapy resistance and represent an unmet clinical need. Chimeric antigen receptor (CAR) T-cells might be a promising therapeutic option for TP53-mutant AML/MDS. However, the impact of TP5...

Full description

Bibliographic Details
Main Authors: Jan Mueller, Roman R Schimmer, Christian Koch, Florin Schneiter, Jonas Fullin, Veronika Lysenko, Christian Pellegrino, Nancy Klemm, Norman Russkamp, Renier Myburgh, Laura Volta, Alexandre PA Theocharides, Kari J Kurppa, Benjamin L Ebert, Timm Schroeder, Markus G Manz, Steffen Boettcher
Format: Article
Language:English
Published: Springer Nature 2024-02-01
Series:EMBO Molecular Medicine
Subjects:
TP53 Mutations
CAR T-Cell Therapy
AML
Mevalonate Pathway
Online Access:https://doi.org/10.1038/s44321-024-00024-2

Internet

https://doi.org/10.1038/s44321-024-00024-2

Similar Items